WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT), announced that it has received a non-binding letter of intent to sell its preclinical oncology aPKCi inhibitor platform for $7 million in upfront cash or tradable stock. The proposed agreement also includes up to $130 million in milestone payments, starting with the launch of a Phase 1 clinical trial, along with high single-digit royalties that could potentially reach $1.5 billion over the life of the drug.
Under the terms, the potential buyer also has options to acquire Windtree’s cardiovascular drug candidates at additional consideration and engage the company as a manufacturing agent for Evofem Biosciences’ FDA-approved product. Windtree has 21 days to close the oncology aPKCi portion of the agreement.
“Windtree is executing our refined corporate strategy to pursue opportunities in growing industries to become a revenue-generating company,” said Jed Latkin, Chief Executive Officer of Windtree Therapeutics. “This offer may provide the company non-dilutive cash and the potential for a very lucrative milestone and royalty stream.”
Latkin emphasized that the preclinical oncology assets are not central to the company’s long-term vision. “We do not view the preclinical oncology aPKCi assets as a core part of our strategy going forward, but want to ensure our current shareholders benefit from their development,” he said. “We are very intently looking at all options to increase shareholder value by reducing the current cashflow burn and focusing on near-term accretive opportunities.”
The proposal reflects Windtree’s broader efforts to reposition itself as a revenue-focused organization. By divesting non-core assets and exploring high-potential partnerships, the company aims to secure steady cash flow while refocusing resources on strategic priorities.
If finalized, the transaction could provide Windtree with a valuable financial cushion while unlocking long-term revenue potential through royalties and milestone payments tied to the aPKCi inhibitor platform’s success in the oncology market.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.